Nov 8 (Reuters) - Valeant Pharmaceuticals International Inc
on Tuesday cut its revenue forecast for the year and
warned that 2017 could be even more challenging as some products
face new competition, sending shares down more than 20 percent.
Read more
No comments:
Post a Comment